{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:08:51Z","timestamp":1789016931132,"version":"build-2803163510"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The phase 3 EA5142\/ALCHEMIST study of adjuvant nivolumab for completely resected EGFR\/ALK-negative non\u2013small cell lung cancer (NSCLC) is being widely interpreted as a negative trial. Its immediate clinical significance is that nivolumab monotherapy, given after the completion of standard postoperative treatment, did not offer a disease-free survival advantage in this population. However, inconsistent results from adjuvant, neoadjuvant, and perioperative trials raise unanswered questions about treatment sequencing, residual disease burden, biomarker selection, and trial design. We propose a hypothesis-generating timing \u00d7 molecular residual disease (MRD) framework to organize these questions, while recognizing that cross-trial comparisons cannot establish either treatment timing or MRD status as a causal determinant of efficacy. NADIM-Adjuvant is the first trial to demonstrate that postoperative circulating tumor DNA positivity can serve as a prognostic marker; however, these data do not confirm MRD as a predictive biomarker for response to chemoimmunotherapy. We also assess an antibody-biology hypothesis mediated by the interplay between immunoglobulin G subclasses and Fc\u03b3 receptors that may drive inter-agent heterogeneity, although this has not been clinically established in resected NSCLC. These considerations collectively identify several testable hypotheses for future adjuvant trials, without diminishing the negative clinical outcome of EA5142.<\/jats:p>","DOI":"10.3389\/fonc.2026.1941683","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:29:19Z","timestamp":1789014559000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond a negative trial: timing, molecular residual disease, and antibody biology in adjuvant immunotherapy for resected NSCLC"],"prefix":"10.3389","volume":"16","author":[{"given":"Sat\u0131 Co\u015fkun","family":"Yazgan","sequence":"first","affiliation":[{"name":"Ankara University School of Medicine, Department of Medical Oncology","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Berna","family":"K\u00f6ksoy","sequence":"additional","affiliation":[{"name":"Ankara University School of Medicine, Department of Medical Oncology","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Akbulut","sequence":"additional","affiliation":[{"name":"Ankara University School of Medicine, Department of Medical Oncology","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2026.8992","article-title":"Adjuvant nivolumab vs observation in resected non-small cell lung cancer: a randomized clinical trial","volume":"336","author":"Chaft","year":"2026","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.jtho.2025.09.022","article-title":"PL03.10 Adjuvant chemotherapy (CT) vs CT-immunotherapy for R0 stage IB-IIIA NSCLC patients (NADIM ADJUVANT): a randomized, phase 3 trial","volume":"20","author":"Provencio","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00292","article-title":"Fc\u03b3R-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13427","article-title":"Fc effector function of immune checkpoint blocking antibodies in oncology","volume":"328","author":"Martineau","year":"2024","journal-title":"Immunol Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41698-025-00984-9","article-title":"A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer","volume":"9","author":"Boukouris","year":"2025","journal-title":"NPJ Precis Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1941683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:29:19Z","timestamp":1789014559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1941683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":13,"alternative-id":["10.3389\/fonc.2026.1941683"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1941683","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1941683"}}